Stockreport

CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value [Seeking Alpha]

CG Oncology, Inc.  (CGON) 
PDF Data from phase 3 BOND-003 study turning out positive, could possibly mean an ability for the company to file a New Drug Application to the FDA in 1st half of 2025. A [Read more]